I was quite direct and clear. You are either antagonistic or you are not actually abreast of the mechanics of how things worked with ODAC and the FDA, the briefing notes and vote.
Since you are an expert at the copy and paste, I have copied my question from my post and pasted it below...
Can you explain why the FDA did not want this to be included in the vote?
Ann: MSB Wins Fierce Biotech Innovation Award for Remestemcel-L, page-146
-
- There are more pages in this discussion • 86 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
98.0¢ |
Change
-0.010(1.01%) |
Mkt cap ! $1.118B | |||
| Open | High | Low | Value | Volume |
| 99.5¢ | $1.02 | 97.0¢ | $2.821M | 2.832M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 20688 | 97.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 99.0¢ | 35000 | 3 |
View Market Depth
| Last trade - 16.10pm 15/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |